Did oral semaglutide work equally well in older adults in PIONEER-1?

Yes, patients aged 65 and older showed A1C reductions statistically indistinguishable from younger patients at all three doses. GI side effects, not efficacy, are the more relevant age-related consideration.

Was there a difference in response between men and women?

No clinically meaningful difference. Women experienced numerically higher rates of nausea, but A1C reductions were similar across sexes at the 14 mg dose.

Does baseline A1C affect how well oral semaglutide works?

Higher baseline A1C predicted larger absolute A1C reductions. Patients starting above 9.0% saw drops exceeding 2.0%, while those below 8.0% saw approximately 1.0%. This pattern is common across diabetes drug classes.

Did BMI affect response to oral semaglutide in PIONEER-1?

Patients with BMI ≥30 showed marginally greater A1C reductions, likely related to the additional benefit of weight loss on insulin sensitivity. The difference was not statistically significant as a formal interaction.

Was PIONEER-1 racially diverse enough to draw conclusions?

No. Approximately 73% of participants were White. Black and Asian subgroups were too small (around 6% and 4%) for reliable effect estimation. Later PIONEER trials and pooled analyses provide somewhat more diverse data.

Does diabetes duration matter for oral semaglutide response?

Patients with shorter diabetes duration (under 5 years) showed numerically better responses, consistent with greater residual beta-cell function. This supports earlier initiation of GLP-1 RA therapy.

Can PIONEER-1 data be applied to patients with kidney disease?

Only for mild renal impairment (eGFR 60, 89). The trial excluded patients with eGFR below 60. PIONEER-5 separately studied moderate renal impairment and showed preserved efficacy.

What is the difference between the two estimands used in PIONEER-1?

The treatment policy estimand includes all patients regardless of rescue medication use, reflecting real-world outcomes. The trial product estimand excludes data after rescue or discontinuation, isolating the drug's pharmacological effect. Subgroup results can differ between them.

Should prescribers choose oral semaglutide over injectable GLP-1 RAs based on subgroup data?

PIONEER-1 subgroup data do not directly compare oral vs. injectable forms. PIONEER-4 compared oral semaglutide to subcutaneous liraglutide. The choice should factor in patient preference, adherence likelihood, and formulary access alongside efficacy data.

Were there subgroups where oral semaglutide clearly did not work?

No subgroup showed a null or negative effect at the 14 mg dose. The smallest responses occurred in patients with lower baseline A1C, which is expected and does not indicate treatment failure.

PIONEER-1 Subgroup Analyses: Who Responded Most and Least to Oral Semaglutide

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Field | Detail | |---|---| | Trial | PIONEER-1 (NCT02906930) | | N | 703 | | Intervention | Oral semaglutide 3 mg, 7 mg, or 14 mg once daily | | Comparator | Placebo | | Duration | 26 weeks | | Population | Adults with T2D inadequately controlled on diet/exercise alone | | Primary endpoint | Change in A1C from baseline (week 26) | | Key result | A1C reduction of 1.5% with 14 mg vs. 0.02% with placebo (treatment policy estimand) |

Why Subgroup Data Matters Here

The primary PIONEER-1 publication reported headline efficacy that placed oral semaglutide alongside injectable GLP-1 receptor agonists. But mean treatment effects mask real variation. A prescriber deciding between oral semaglutide and, say, an SGLT2 inhibitor for a 72-year-old woman with a BMI of 27 needs to know whether the 1.5% A1C drop holds in her demographic profile, or whether it was driven by younger, heavier patients with very high baseline glycemia.

PIONEER-1 pre-specified subgroup analyses by baseline A1C, age, sex, body weight, BMI, and diabetes duration. Post-hoc analyses extended to race/ethnicity and renal function categories. The FDA's prescribing information for Rybelsus incorporates pooled subgroup data from the entire PIONEER program but does not break out trial-level subgroup detail, making the original trial data the primary reference for granular interpretation.

Baseline A1C: The Strongest Predictor of Absolute Response

Across the PIONEER program and in PIONEER-1 specifically, baseline A1C was the single most influential modifier of absolute A1C change. This pattern, sometimes called the "higher they start, harder they fall" principle, is not unique to semaglutide. It appears across nearly every glucose-lowering drug class. But the magnitude here is clinically relevant for prescribing decisions.

HealthRX Subgroup Response Framework for PIONEER-1 (14 mg dose)

| Subgroup factor | Category | Estimated A1C change from baseline | Relative to overall mean (−1.5%) | |---|---|---|---| | Baseline A1C | <8.0% | −0.9% to −1.1% | Below mean | | | 8.0 to 9.0% | −1.4% to −1.6% | Near mean | | | >9.0% | −1.8% to −2.1% | Above mean | | Age | <65 years | −1.5% | At mean | | | ≥65 years | −1.4% | Near mean | | Sex | Male | −1.5% | At mean | | | Female | −1.4% | Near mean | | BMI | <30 kg/m² | −1.4% | Near mean | | | ≥30 kg/m² | −1.5% | At mean | | Diabetes duration | <5 years | −1.5% to −1.6% | At or above mean | | | ≥5 years | −1.3% to −1.5% | At or slightly below mean |

Values synthesized from the PIONEER-1 trial pre-specified subgroup forest plots and supplementary data. Ranges reflect the treatment policy and trial product estimands.

Patients entering the trial with A1C above 9.0% experienced reductions exceeding 2.0% in some analyses. This does not mean the drug "works better" in these patients in a pharmacological sense. Beta-cell responsiveness to incretin stimulation and the statistical phenomenon of regression to the mean both contribute. Still, the clinical implication is straightforward: oral semaglutide 14 mg can produce large absolute A1C drops in patients starting with meaningfully elevated glycemia, even as monotherapy without background metformin.

Age and Sex: Reassuringly Flat

The PIONEER-1 subgroup analyses showed no statistically significant interaction between age category and treatment effect. Patients aged 65 and older responded similarly to younger patients. This is important because older adults metabolize peptides differently, often have reduced GI motility (which affects oral semaglutide absorption), and frequently carry more comorbidities that could blunt drug response.

The sex-based analysis was equally unremarkable. Male and female participants showed overlapping confidence intervals at all three doses. The ADA Standards of Care do not distinguish between sexes when recommending GLP-1 RAs, and PIONEER-1 data support that position.

One nuance: women in the trial experienced numerically (not statistically) higher rates of nausea. GI tolerability, not efficacy, may be the more relevant sex-based consideration in clinical practice.

BMI: Modest but Real Interaction

Body weight and BMI subgroups showed a small but consistent pattern. Patients with BMI ≥30 kg/m² had marginally greater A1C reductions than those below 30. The difference was not statistically significant as an interaction term, but the direction aligns with mechanistic expectations. GLP-1 receptor agonists reduce appetite and body weight. Patients with more adiposity have more weight to lose, and weight loss itself improves insulin sensitivity.

At the 14 mg dose, mean body weight loss was approximately 3.7 kg vs. 1.4 kg with placebo over 26 weeks. The weight effect was more pronounced in the higher BMI subgroup, and this likely contributed to the slightly greater glycemic response. For prescribers weighing oral semaglutide against DPP-4 inhibitors (which are weight-neutral) or sulfonylureas (which cause weight gain), this interaction adds clinical relevance even if it did not reach formal significance.

Race and Ethnicity: The Data Gap

PIONEER-1 enrolled patients across 16 countries, but the racial composition was predominantly White (approximately 73%). Hispanic/Latino participants comprised roughly 16% of the cohort. Black/African American participants made up only about 6%, and Asian participants were similarly underrepresented at around 4%.

The published subgroup data did not show differential efficacy by race, but the confidence intervals for minority subgroups were wide enough to be nearly uninformative. A subgroup of ~42 Black patients (6% of 703) cannot generate reliable effect estimates.

This is not a criticism unique to PIONEER-1. The FDA's 2020 guidance on diversity in clinical trials explicitly acknowledges that most diabetes trials underrepresent Black and Hispanic populations despite their disproportionately higher T2D burden. Later trials in the PIONEER program (particularly PIONEER-6 and the cardiovascular outcomes data) enrolled somewhat more diverse cohorts, but true racial equity in GLP-1 trial data remains elusive.

For prescribers treating Black or Hispanic patients, the honest statement is: oral semaglutide probably works similarly based on mechanism and pooled program data, but PIONEER-1 alone cannot confirm it.

Diabetes Duration: Earlier Treatment, Bigger Effect?

Patients with diabetes duration under 5 years showed numerically greater A1C reductions than those with longer disease history. This aligns with a well-established biological gradient: shorter diabetes duration correlates with greater residual beta-cell function, meaning more insulin-secretory capacity for GLP-1 RA stimulation to act on.

The clinical translation is direct. Starting oral semaglutide earlier in the disease course, rather than waiting until multiple oral agents have failed, may yield better glycemic control. The ADA/EASD consensus report supports early consideration of GLP-1 RAs, particularly in patients with established cardiovascular disease or high cardiovascular risk, and PIONEER-1 subgroup data add mechanistic support for this timing.

Renal Function Subgroups

Post-hoc analyses stratified by estimated glomerular filtration rate (eGFR) showed preserved efficacy in patients with mild renal impairment (eGFR 60 to 89 mL/min/1.73m²). The trial excluded patients with eGFR <60, so moderate-to-severe CKD cannot be addressed from PIONEER-1 data alone. PIONEER-5, a dedicated renal impairment trial, later demonstrated oral semaglutide efficacy in patients with eGFR 30, 59.

The Rybelsus prescribing information does not require dose adjustment for renal impairment, consistent with the peptide's hepatic metabolism rather than renal clearance.

Methodological Notes on Subgroup Interpretation

PIONEER-1 used two estimands, and this matters for subgroup interpretation. The "treatment policy" estimand included all randomized patients regardless of adherence or rescue medication use. The "trial product" estimand excluded data after treatment discontinuation or rescue initiation. Subgroup results can differ meaningfully depending on which estimand is applied.

In the higher baseline A1C subgroup, the treatment policy estimand showed a smaller effect than the trial product estimand. Why? Patients with A1C above 9.0% were more likely to require rescue medication (per protocol, rescue was offered if A1C exceeded pre-specified thresholds). Once rescue medication was added, the treatment policy estimand attributed the combined drug effect, diluting the semaglutide-specific signal.

For real-world prescribing, the treatment policy estimand is arguably more relevant: it reflects what happens to the average patient you start on the drug, including those who will need add-on therapy. But for understanding the drug's pharmacological ceiling, the trial product estimand is more informative.

PIONEER-1 was not powered for subgroup interaction testing. All interaction p-values should be interpreted as exploratory. A non-significant interaction does not prove subgroup equivalence. It may simply reflect inadequate sample size to detect a real difference.

Limitations the Authors Acknowledged

The original publication and supplementary materials noted several constraints. The 26-week duration limits durability conclusions. The monotherapy design (diet and exercise background only) does not reflect typical real-world prescribing, where most patients receive oral semaglutide on top of metformin. Subgroup sizes for race/ethnicity were too small for reliable inference. The dose-escalation schedule (4 weeks at 3 mg, then 4 weeks at 7 mg, then 14 mg maintenance) means the full 14 mg exposure period was only 18 weeks, potentially underestimating the steady-state effect.

Frequently asked questions

›

References

Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-1732. PubMed
U.S. Food and Drug Administration. Rybelsus (semaglutide) prescribing information. 2019. FDA Label
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the ADA and EASD. Diabetes Care. 2018;41(12):2669-2701. PubMed
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1). PubMed
Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5). Lancet Diabetes Endocrinol. 2019;7(7):515-527. PubMed